Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: Final analysis from a multicenter Italian study.

被引：4
|
作者：
Caffo, Orazio
Bria, Emilio
De Giorgi, Ugo
Tucci, Marcello
Galli, Luca
Fratino, Lucia
Rossetti, Sabrina
Iacovelli, Roberto
Lo Re, Giovanni
Mosillo, Claudia
Gasparro, Donatello
Guglielmini, Pamela Francesca
Damiani, Azzurra
Procopio, Giuseppe
De Lisi, Delia
Ruatta, Fiorella
Scagliarini, Sarah
Donini, Maddalena
Sperduti, Isabella
Basso, Umberto
机构：
[1] Santa Chiara Hosp, Med Oncol, Trento, Italy
[2] Univ Verona, Verona, Italy
[3] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Meldola, Italy
[4] San Luigi Hosp, Orbassano, Italy
[5] Azienda Osped Univ Pisana, Pisa, Italy
[6] Natl Canc Ctr CRO, Aviano, Italy
[7] Ist Nazl Tumori Fdn G Pascale IRCCS, Div Med Oncol, Dept Uro Gynaecol Oncol, Naples, Italy
[8] Univ Verona, Azienda Osped Univ Integrata, Med Oncol, Verona, Italy
[9] Santa Maria Angeli Gen Hosp, Pordenone, Italy
[10] Sapienza Univ Rome, Policlin Umberto 1, Rome, Italy
[11] Azienda Osped Univ Parma, Parma, Italy
[12] SS Antonio & Biagio & Cesare Arrigo Gen Hosp, Oncol, Alessandria, Italy
[13] Azienda Osped Univ San Martino, Genoa, Italy
[14] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[15] Campus Bio Med Univ Rome, Dept Med Oncol, Rome, Italy
[16] Fdn Piemonte Oncol IRCCS, Med Oncol, Candiolo, Italy
[17] Cardarelli Hosp, Naples, Italy
[18] Osped Cremona, SC Oncol, Cremona, Italy
[19] Regina Elena Inst Canc Res, Biostat Unit, Rome, Italy
[20] Ist Oncol Veneto IOV IRCCS, Dept Clin & Expt Oncol, Med Oncol Unit, Padua, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.5030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5030
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Impact of prior antiandrogen exposure on clinical outcomes in patients (pts) receiving abiraterone acetate (AA): Results from a randomized study (COU-AA-301) in metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel (D)
    Bellmunt, J.
    Yu, M. K.
    Kheoh, T.
    Taplin, M. E.
    Davis, I. D.
    Schnjvers, D.
    Protheroe, A.
    Molina, A.
    De Bono, J. S.
    Scher, H. I.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S695 - S695
  • [42] Impact of treatment sequence in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Data from the prospective PROREPAIR-B study
    Cattrini, C.
    Romero Laorden, N.
    Castro, E.
    Garcia-Carbonero, I.
    Piulats, J. M.
    Puente, J.
    Valderrama, B. P.
    Villa Guzman, J. C.
    Gonzalez Billalabeitia, E.
    Morales Barrera, R.
    Lozano Mejorada, R.
    Luque, R.
    Martinez Ortega, E.
    Arranz Arija, J. A.
    Gallardo Diaz, E.
    Pinto Marin, A.
    Almagro Casado, E.
    Mendez Vidal, M. J.
    Olmos Hidalgo, D.
    Lorente, D.
    ANNALS OF ONCOLOGY, 2019, 30
  • [43] Fatigue Improvement/Reduction With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel - Results From the COU-AA-301 Phase 3 Study
    Sternberg, C. N.
    Scher, H. I.
    Molina, A.
    North, S.
    Mainwaring, P.
    Hao, Y.
    Gagnon, D.
    Kheoh, T.
    Haqq, C. M.
    de Bono, J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S488 - S489
  • [44] Abiraterone Acetate Improves Functional Status in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Post-docetaxel - Results From the COU-AA-301 Phase 3 Study
    Harland, S.
    de Bono, J. S.
    Haqq, C. M.
    Staffurth, J. N.
    Hao, Y.
    Gagnon, D.
    Liu, C.
    Sternberg, C. N.
    Molina, A.
    Scher, H. I.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S484 - S484
  • [45] Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) pts receiving a new agent (NA)-based third line treatment: Final results from a multicenter Italian study.
    Caffo, Orazio
    Bria, Emilio
    De Giorgi, Ugo
    Tucci, Marcello
    Biasco, Elisa
    Fratino, Lucia
    Facchini, Gaetano
    Iacovelli, Roberto
    Lo Re, Giovanni
    Scagnoli, Simone
    Morelli, Franco
    D'Angelo, Alessandro
    Verderame, Francesco
    Campadelli, Enrico
    Ricotta, Riccardo
    Napolitano, Martina
    Sartori, Donata
    Borsellino, Nicolo
    Sperduti, Isabella
    Maruzzo, Marco
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [46] Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Posadas, Edwin M.
    Bruce, Justine Yang
    Lim, Emerson A.
    Petrylak, Daniel Peter
    Peng, Weimin
    Maul, Raymond Scott
    Smit, Hans W.
    Tran, Namphuong
    Nanus, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] Long-term outcomes and predictive factors in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) showing abiraterone withdrawal syndrome (AWS) after docetaxel (DOC) treatment.
    Caffo, Orazio
    Maines, Francesca
    Trentin, Chiara
    Veccia, Antonello
    Galligioni, Enzo
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [48] Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).
    Smith, Matthew Raymond
    De Bono, Johann Sebastian
    Sternberg, Cora N.
    Le Moulec, Sylvestre
    Oudard, Stephane
    De Giorgi, Ugo
    Krainer, Michael
    Bergman, Andre M.
    Hoelzer, Wolfgang
    De Wit, Ronald
    Boegemann, Martin
    Saad, Fred
    Cruciani, Giorgio
    Thiery-Vuillemin, Antoine
    Feyerabend, Susan
    Miller, Kurt
    Ramies, David Albert
    Hessel, Colin
    Weitzman, Aaron
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [49] Comparison of two doses of cabazitaxel plus prednisone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen
    Eisenberger, Mario A.
    Hardy-Bessard, Anne-Claire
    Mourey, Loic
    Mainwaring, Paul N.
    Ford, Daniel
    Shapiro, Jeremy David
    Carles, Joan
    Ng, Siobhan
    Gil, Thierry
    Alekseev, Boris
    Ivanov, Sergey
    Facchini, Thomas
    Legouffe, Eric
    Apolikhin, Oleg
    Pandha, Hardev S.
    Beeker, Aart
    Karyakin, Oleg
    Zhang, Wendy
    Chadjaa, Mustapha
    De Bono, Johann Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Real-world analysis of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving vs not receiving chemotherapy in the treatment sequence
    Morgans, A. K.
    Divan, H. A.
    Birtle, A. J.
    Dorff, T.
    Ozatilgan, A.
    Graff, J. N.
    ANNALS OF ONCOLOGY, 2019, 30 : 334 - 334
12345